mRNA expression of IDO1, IDO2 and HLA-G5 in breast cancer patients were respectively 2.9, 1.6 and 2.2 fold more than normal individuals, although these differences were not statistically significant (P=0.17, 0.85 and 0.81, respectively). This evidence concerns the gene IDO2 and breast carcinoma.